Medicine Regulation - Political And Legal Frameworks I Flashcards

1
Q

What are medicinal products (NOT medicines)

A

For preventing or treating disease in human beings

Restoring, correcting or modifying a physiological function by exerting a pharmacological, immunological or metabolic
action

Making a medical diagnosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Does blood count as a medicinal product?

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Modern medicines legislation in the UK was triggered by which tragedy?

A

Thaolidomide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Who are the regulators fro medicines and licensing?

A

Medicines and Healthcare products Regulatory Agency (MHRA)
an executive agency of the Department of Health and Social Care

The MHRA is also enforcement authority for licensing matters in the UK.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Marketing authorisations for human medicines

A

Human Medicines Regulations 2012

A person may not sell or supply or offer to sell or supply a medicinal product unless that product has a UK marketing authorisation

Summary of Product Characteristics (SmPC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is off-label prescribing?

A

Treating a patient who has a condition for which the product does not have a marketing authorisation

A marketing authorisation can be given to treat one condition but not another condition for which it may nevertheless be effective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is an example of off-label prescription?

A

Medicine for migraines

Medicine for period pains

THEY must be covered by the authorisation and licensed appropriately

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Revocation, variation or suspension
LIST at least 5 points:

A

A. Harmful or ineffective
B. Incorrect information
C. Breach of licence
D. Unfulfilled licence
E. Information not provided
F. No longer EU based
G. Non-compliance with Good Manufacturing
Practice (GMP)
H. Unfulfilled licence (non-UK)
I. Public at risk
J. Apply for change
K. Poor manufacturing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

E. No longer EU based, affect of Brexit?

A

It may cause shortages in products which are not from the EU, and therefore have not been stockpiled by suppliers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

J. Apply for change, by authorities

A

If there is any additional info to be added

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Orphan drugs

A

Used to treat conditions that occur infrequently

Cost of R&D would not be recovered by the expected sales

Therefore;
the pharmaceutical industry would be unwilling to develop the medicinal product under normal market conditions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

To qualify for orphan designation:

A

for a disease that is life-threatening or chronically debilitating not more than 5 in 10,000 no satisfactory method exists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are generics?

A

Have the same composition as a Reference Medicinal Products (RMPs)
Has the same pharmaceutical form
Appropriate bioavailability studies (demonstrated bioequivalence)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Generic products are usually _______ that branded medicines.

A

cheaper

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Is there guaranteed safety with generic products?

A

yes, same formula

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What if there is changes to the branded medicines?

A

need another authorisation check as the target area may be different in tablets than capsules

17
Q

NHS need to re-emburse pharmacies all over the UK - why use generic products instead of branded?

A

Cheaper - positive economic effect

18
Q

Why use brands FOR generic?

A

When a prescription is being written, it may be this specific brand that is needed to be dispensed for that patient

19
Q

Different brand names mean…

A

Once a patent expires, other companies can develop their own version of the medicine.

These are known as generic brands.

Their active ingredient name always remains the same, but they are marketed under different brand names.

20
Q

Abridged procedures

A

Manufacturers will have incurred the considerable cost of years of R&D

A competitor can rely on the data for the original product only after the passage of a data exclusivity period.

The data exclusivity period is eight years for products that have been authorised in the UK.

21
Q

Early Access to Medicines Scheme (EAMS)
which enables…

A

Enables patients to have access to medicines which have not yet been authorised

22
Q

What is special about the EAMS

A

life-threatening or seriously debilitating conditions

no suitable alternative

Voluntary - relying on the public/ healthcare professionals

23
Q

Define Pharmacovigilance:

A

Detection, assessment, understanding and prevention of adverse effects or any other drug-related problem

24
Q

Why is Pharmacovigilance important?

A

Promote the safe and effective use of drugs by providing reliable information

Information obtainable before a medicine is placed on the market is ultimately limited

25
Q

Are licensing authorities involved with pharmacovigilance?

A

Both the licensing authority and holders of manufacturing authorisations must operate a pharmacovigilance system

Capture and evaluate all information

Take all appropriate measures to minimise and prevent risk.

26
Q

What is the yellow card scheme?

A

MHRA

Collecting and monitoring information on suspected safety concerns or incidents involving medicines and medical devices.

Voluntary reporting

Early warning that the safety of a product may require further investigation.

27
Q

Is the yellow card scheme relied upon?

A

The Cumberlege Review (2020) concluded that the Yellow Card scheme could not be relied upon to identify promptly significant adverse outcomes.

28
Q

Where can we find the yellow pages?

A

At the back of the BNF